AOD-9604 vs Semaglutide

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicAOD-9604Semaglutide
What it is

A synthetic 16-amino-acid fragment of human growth hormone (residues 177 to 191 plus an added tyrosine), according to FDA’s 2024 evaluation.1

A GLP-1 receptor agonist. The Wegovy label describes semaglutide as a GLP-1 analogue with 94% sequence similarity to human GLP-1.4

FDA status

Not FDA-approved

Not FDA-approved; FDA advised against adding it to the compounding list1,2,3

Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3

Is AOD-9604 FDA-approved?

FDA-approved

FDA-approved as Ozempic, Rybelsus and Wegovy4,5,6,7

FDA-approved. Drugs@FDA lists Ozempic (first approved December 5, 2017), Rybelsus (September 20, 2019) and Wegovy (June 4, 2021). The Wegovy label carries a boxed warning about thyroid C-cell tumors seen in rodents.4,5,6,7

Is semaglutide FDA-approved?

HHS compounding policy, October 30, 2026

Not among the six peptides the policy lists.8

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. AOD-9604 is not among them.8,9

Not among the six peptides the policy lists.8

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.3

Not addressed in this profile’s sources.

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study The OPTIONS trial: a randomized, double-blind, placebo-controlled weight-loss trial that enrolled 536 adults, known from company filings; FDA found no published report of its methods and results.1
  • Small, short, or incompletely reported human study Six randomized, placebo-controlled company studies summarized in a 2013 safety publication, which FDA found lacked detail on methods and results.1
  • Animal or laboratory research Rodent studies reporting less fat formation and lower body weight, and rat and monkey toxicology studies with possible effects on bone turnover and the liver, described in FDA’s evaluation.1

Large randomized human trials

  • Large randomized human trial A double-blind, placebo-controlled cardiovascular trial (NCT03574597) that randomized 17,604 adults aged 45 or older with established cardiovascular disease and obesity or overweight, without diabetes. The label reports a hazard ratio of 0.80 for major adverse cardiovascular events.4
  • Large randomized human trial A 68-week randomized, double-blind, placebo-controlled weight trial (NCT03548935) in 1,961 adults with obesity, or overweight with a weight-related condition, that excluded type 2 diabetes. It is one of several weight trials the label describes.4
  • Large randomized human trial A randomized, double-blind, placebo-controlled MASH trial (NCT04822181) whose week-72 analysis included 800 adults with moderate to advanced liver fibrosis.4
Records collected

0 ClinicalTrials.gov records and 2 PubMed records collected

140 ClinicalTrials.gov records and 108 PubMed records collected

Area of study

Metabolic and weight1

Metabolic and weight, Heart and blood vessels, Liver4

Latest dated events
  1. FDA’s compounding safety-risk page, as last updated, lists AOD-9604 among withdrawn nominations with safety concerns.3
  2. FDA’s Pharmacy Compounding Advisory Committee votes 12 to 0 against placing AOD-9604 on the list.2
  3. FDA staff date their evaluation recommending against adding AOD-9604 to the 503A bulks list.1
  1. FDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.10
  2. DailyMed publishes the Wegovy label version cited on this page.4
  3. FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.11

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  2. 2
    December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    WEGOVY (semaglutide) injection and tablet · SPL version 19 · published 2026-06-30 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

  5. 5
    Drugs@FDA application NDA209637 · original submission status AP · 2017-12-05 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  6. 6
    Drugs@FDA application NDA213051 · original submission status AP · 2019-09-20 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  7. 7
    Drugs@FDA application NDA215256 · original submission status AP · 2021-06-04 · dataset 2026-08-13 ↗

    Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

  8. 8
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  9. 9
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  10. 10
    FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  11. 11
    FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗

    U.S. Food and Drug Administration · Official source · Source checked July 29, 2026